MedTrace Logo

2021 PMT iAge® Intervention Trial by Edifice Health

NCT04983017 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 781

Last updated 2024-09-19

No results posted yet for this study

Summary

This is a decentralized, double-blind, randomized, placebo-controlled study to assess the effectiveness of different dietary supplements in decreasing systemic chronic inflammation (SCI) and lowering inflammatory age (iAge®). iAge® is a metric for age-related chronic inflammation and immune function decline calculated from a standard blood draw utilizing immune phenotyping and artificial intelligence algorithms. SCI is a natural process that occurs within the body. It is believed to accelerate the process of biological aging. As opposed to acute inflammation, iAge® is not a reflection of illness, infection, trauma or injury. It naturally occurs in the ambulatory healthy population as we age as a function of the body.

This study will use immunotype specific dietary supplement formulations to improve a participant's Inflammatory Age® (iAge®).

Conditions

Interventions

DIETARY_SUPPLEMENT

Dietary supplement

iron bisglycinate manganese chloride vitamin D2 guar gum indole-3-carbinol L-methionine piceatannol biotin caffeine beta-carotene lutein zinc sulfate

OTHER

Placebo

Matched Placebo to Intervention

Sponsors & Collaborators

  • Edifice Health

    lead INDUSTRY

Principal Investigators

  • David Furman, PhD · Chairman of the Scientific Advisory Board

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-10
Primary Completion
2022-09-09
Completion
2022-09-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04983017 on ClinicalTrials.gov